Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,001–2,100 of 10,906
Chirumbolo, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26922 · Cited by 41
Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
Lupica, A., Stefano, V. D., Iacono, S., Pignolo, A., Quartana, M., Gagliardo, A., Fierro, B., & Brighina, F. (2022) · Neurology International · doi:10.3390/neurolint14020033 · Cited by 40
Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
Tumor-activated IL-2 mRNA delivered by lipid nanoparticles for cancer immunotherapy
Jiang, Y., Zhang, Y., Liu, C., Liu, J., Xue, W., Wang, Z., & Li, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.016 · Cited by 39
Yau, K., Chan, C. T., Abe, K. T., Jiang, Y., Atiquzzaman, M., Mullin, S. I., Shadowitz, E., Liu, L., Kostadinovic, E., Sukovic, T., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.211881 · Cited by 37
Xie, Z., Li, Y., Wang, F., Yang, J., Han, Z., Chen, L., Jiang, W., Zhou, H., Li, T., Tang, Z., et al. (2024) · doi:10.21203/rs.3.rs-5040961/v1 · Cited by 39
Self-citationRolfes, L., Härmark, L., Kant, A. C., van Balveren, L., Hilgersom, W. J. A., & van Hunsel, F. P. A. M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.013 · Cited by 42
Mazur, M., Duś‐Ilnicka, I., Jedliński, M., Ndokaj, A., Janiszewska‐Olszowska, J., Ardan, R., Radwan‐Oczko, M., Guerra, F., Luzzi, V., Vozza, I., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094965 · Cited by 39
Psychiatric adverse reactions to COVID-19 vaccines: A rapid review of published case reports
Balasubramanian, I., Faheem, A., Padhy, S. K., & Menon, V. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103129 · Cited by 39
Wu, X., Shan, K.-J., Zan, F., Tang, X., Qian, Z., & Lü, J. (2023) · Advanced Science · doi:10.1002/advs.202205445 · Cited by 44
Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G. M., Isacco, C. G., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040793 · Cited by 64
Charland, N., Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Trépanier, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00561-2 · Cited by 73
Self-citationChan, L., Fuca, N., Zeldis, E., Campbell, K. N., & Shaikh, A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04080321 · Cited by 39
Eugenia-Toledo-Romaní, M., Verdecia-Sánchez, L., Rodríguez-González, M., Rodríguez-Noda, L., Valenzuela‐Silva, C., Paredes-Moreno, B., Sánchez-Ramírez, B., Pérez-Nicado, R., González-Mugica, R., Hernández-García, T., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.082 · Cited by 42
Kemp, F., Proverbio, D., Aalto, A., Mombaerts, L., d’Hérouël, A. F., Husch, A., Ley, C., Gonçalves, J. M., Skupin, A., & Magni, S. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110874 · Cited by 49
County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States
McLaughlin, J. M., Khan, F. L., Pugh, S. J., Swerdlow, D. L., & Jódar, L. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100191 · Cited by 52
Held, J., Esse, J., Taşçılar, K., Steininger, P. A., Schober, K., Irrgang, P., Alsalameh, R. J., Tenbusch, M., Seggewies, C., & Bogdan, C. (2021) · Vaccines · doi:10.3390/vaccines9101063 · Cited by 40
Du, Y., Chen, L., & Shi, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.829176 · Cited by 46
Ferretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
“Children and adolescents outside of these authorized age groups should not receive COVID-19 vaccination at this time as well as pregnant women, since they have been excluded from the trials (4, 5).”
BackgroundShaker, M. S., Abrams, E. M., & Greenhawt, M. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.054 · Cited by 42
Sadeghi, S., Kalantari, Y., Shokri, S., Fallahpour, M., Nafissi, N., Goodarzi, A., & Valizadeh, R. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105196 · Cited by 45
Šťastná, D., Menkyová, I., Drahota, J., Hrnčiarová, T., Havrdová, E., Vachová, M., Andělová, M., Kleinová, P., Kovářová, I., Krasulová, E., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104014 · Cited by 40
Chung, N., Chen, Y.-C., Yang, S.-J., Lin, Y., Dou, H.-Y., Wang, L. H.-C., Liao, C., & Chow, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.024 · Cited by 43
Villadiego, J., García‐Arriaza, J., Ramírez‐Lorca, R., García‐Swinburn, R., Cabello-Rivera, D., Rosales‐Nieves, A. E., Álvarez-Vergara, M. I., Cala-Fernández, F., García‐Roldán, E., López-Ogáyar, J. L., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01242-y · Cited by 46
Leveraging deep learning to improve vaccine design
Hederman, A. P., & Ackerman, M. E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.002 · Cited by 45
Li, Y.-R., Dunn, Z. S., Garcia, G., Carmona, C., Zhou, Y., Lee, D. P. H., Yu, J., Huang, J., Kim, J. T., Arumugaswami, V., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02787-2 · Cited by 42
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 53
Sadremomtaz, A., Al-Dahmani, Z. M., Ruiz-Moreno, A. J., Monti, A., Wang, C., Azad, T., Bell, J. C., Doti, N., Velasco-Velázquez, M. A., de Jong, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00477 · Cited by 40
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 43
(2021) · doi:10.1101/2021.03.24.436620 · Cited by 68
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2131767 · Cited by 37
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
Lora, A. J. M., Long, J. E., Huang, Y., Baden, L. R., Sahly, H. M. E., Follmann, D. A., Goepfert, P., Gray, G., Grinsztejn, B. G. J., Kotloff, K. L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.51974 · Cited by 42
Self-citationSARS-CoV-2 vaccines in patients with SLE
Tang, W., Askanase, A., Khalili, L., & Merrill, J. T. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000479 · Cited by 39
Košárková, A., Maliňáková, K., van Dijk, J. P., & Tavel, P. (2021) · Vaccines · doi:10.3390/vaccines9101157 · Cited by 44
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Pan, S., Fan, R., Han, B. R., Tong, A., & Guo, G. F. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.003 · Cited by 43
Yaamika, H., Muralidas, D., & Elumalai, K. (2023) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2023.08.004 · Cited by 73
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 46
Taha, Y., Wardle, H., Evans, A. B., Hunter, E., Marr, H. J., Osborne, W., Bashton, M., Smith, D., Burton-Fanning, S., Schmid, M. L., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00491-2 · Cited by 40
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Wang, H., Wang, Z.-G., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27175607 · Cited by 47
Paun, R. A., Jurchuk, S., & Tabrizian, M. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10601 · Cited by 57
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Frara, S., Loli, P., Allora, A., Santini, C., di Filippo, L., Mortini, P., Fleseriu, M., & Giustina, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09672-y · Cited by 44
Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection
Christodoulou, I., Rahnama, R., Ravich, J. W., Seo, J., Zolov, S. N., Marple, A., Markovitz, D. M., & Bonifant, C. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763460 · Cited by 38
Zhang, S., Ponce, J., Zhang, Z., Lin, G., & Karniadakis, G. E. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009334 · Cited by 42
Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19
Lindner, H. A., Velásquez, S. Y., Thiel, M., & Kirschning, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.602130 · Cited by 41
Clinical manifestations of COVID‐19 breakthrough infections: A systematic review and meta‐analysis
Lee, C. J., Woo, W., Kim, A. Y., Yon, D. K., Lee, S. W., Koyanagi, A., Kim, M. S., Tizaoui, K., Dragioti, E., Raduà, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27871 · Cited by 43
Lind, M. L., Dorión, M., Houde, A. J., Lansing, M., Lapidus, S., Thomas, R., Yildirim, I. B., Omer, S. B., Schulz, W. L., Andrews, J. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40750-8 · Cited by 43
da Trindade, L. R., da Silva, D. V. T., Baião, D. D. S., & Paschoalin, V. M. F. (2021) · Molecules · doi:10.3390/molecules26154621 · Cited by 42
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 42
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 41
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Hasegawa, S., Tholany, J., Perencevich, E. N., Maezato, A. M., Ricardo, V. C. V., Salinas, J. L., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.336 · Cited by 41
Immune Dysfunction and Infection Risk in Advanced Liver Disease
McGettigan, B. M., Hernández‐Tejero, M., Malhi, H., & Shah, V. H. (2025) · Gastroenterology · doi:10.1053/j.gastro.2024.08.046 · Cited by 51
Cacciottolo, M., Nice, J. B., Li, Y., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Chin, E. R., Young, M., Angeles, J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00503-23 · Cited by 39
Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans
Cai, M., Xie, Y., & Al‐Aly, Z. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510226 · Cited by 49
Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
Caffrey, A. R., Appaneal, H. J., Lopes, V., Puzniak, L., Zasowski, E. J., Jódar, L., LaPlante, K. L., & McLaughlin, J. M. (2024) · Nature Communications · doi:10.1038/s41467-024-53842-w · Cited by 41
Benschop, R. J., TUTTLE, J. L., Zhang, L., Poorbaugh, J., Kallewaard, N. L., Vaillancourt, P., Crisp, M., Trinh, T. N. V., Freitas, J. J., Beasley, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3041 · Cited by 38
Self-citationEvaluating how cationic lipid affects mRNA-LNP physical properties and biodistribution
Guéguen, C., Chimol, T. B., Briand, M., Renaud, K., Seiler, M., Ziesel, M., Erbacher, P., & Hellal, M. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.08.002 · Cited by 42
Critical fluctuations in epidemic models explain COVID-19 post-lockdown dynamics
Aguiar, M., Van-Dierdonck, J. B., Mar, J., Cusimano, N., Knopoff, D. A., Anam, V., & Stollenwerk, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-93366-7 · Cited by 40
COVID-19 and obesity: fighting two pandemics with intermittent fasting
Ealey, K. N., Phillips, J. C., & Sung, H. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.06.004 · Cited by 44
COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases
Lechien, J. R., Diallo, A. O. K., Dachy, B., Bon, S. D. L., Maniaci, A., Vaira, L. A., & Saussez, S. (2021) · Ear Nose & Throat Journal · doi:10.1177/01455613211033125 · Cited by 46
Riccio, M. D., Boccalini, S., Rigon, L., Biamonte, M. A., Albora, G., Giorgetti, D., Bonanni, P., & Bechini, A. (2021) · Vaccines · doi:10.3390/vaccines9060633 · Cited by 44
McDade, T. W., Demonbreun, A. R., Sancilio, A., Mustanski, B. S., D’Aquila, R. T., & McNally, E. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-96879-3 · Cited by 43
Frames that matter: Increasing the willingness to get the Covid-19 vaccines
Diament, S. M., Kaya, A., & Magenheim, E. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.114562 · Cited by 43
Yang, Z., Wang, Y., Jin, Y., Zhu, Y., Wu, Y., Li, C., Kong, Y., Song, W., Tian, X., Zhan, W., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00810-1 · Cited by 37
The hindrances to perform the COVID-19 vaccination in Brazil
Boschiero, M. N., Palamim, C. V. C., & Marson, F. A. L. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1955607 · Cited by 45
Bartesaghi, S., Wallenius, K., Hovdal, D., Liljeblad, M., Wallin, S., Dekker, N., Barlind, L., Davies, N. M., Seeliger, F., Winzell, M. S., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.010 · Cited by 44
Poley, M., Chen, G., Sharf‐Pauker, N., Avital, A., Kaduri, M., Sela, M., Mora‐Raimundo, P., Koren, L., Arber, S., Egorov, E., et al. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200089 · Cited by 44
SARS-CoV-2 variants: biology, pathogenicity, immunity and control
Uraki, R., Korber, B., Diamond, M., & Kawaoka, Y. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01255-x · Cited by 64
“Clinical studies have shown high vaccine effectiveness in preventing severe symptoms and death 10,158,159 , and vaccination is associated with a decreased risk of long COVID 160 .”
The COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study
Beatty, A. L., Peyser, N. D., Butcher, X., Carton, T. W., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021) · JMIR Research Protocols · doi:10.2196/28169 · Cited by 34
The dynamics of trust and communication in COVID-19 vaccine decision making: A qualitative inquiry
Ledford, C. J. W., Cafferty, L. A., Moore, J. X., Roberts, C., Whisenant, E. B., Rychtarikova, A. G., & Seehusen, D. A. (2022) · Journal of Health Communication · doi:10.1080/10810730.2022.2028943 · Cited by 39
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review
Ismail, F. S., Gallus, M., Meuth, S. G., Okada, H., Hartung, H.-P., & Melzer, N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3818 · Cited by 46
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 45
Waning immunity and IgG4 responses following bivalent mRNA boosting
Lasrado, N., Collier, A.-R. Y., Miller, J. J., Hachmann, N. P., Liu, J., Anand, T., Bondzie, E. A., Fisher, J. L., Mazurek, C. R., Patio, R. C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj9945 · Cited by 43
Self-citationMilano, E., Ricciardi, A., Casciaro, R., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27629 · Cited by 38
Mamez, A., Pradier, A., Giannotti, F., Petitpas, A., Urdiola, M. F., Vu, D., Masouridi‐Levrat, S., Morin, S., Dantin, C., Clerc-Renaud, D., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01466-9 · Cited by 38
Lipid-based nanoparticles and RNA as innovative neuro-therapeutics
Tsakiri, M., Zivko, C., Demetzos, C., & Mahairaki, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900610 · Cited by 41
Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era
Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022) · National Science Review · doi:10.1093/nsr/nwac124 · Cited by 43
Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness
Li, K. Q., Shi, X., Miao, W., & Tchetgen, E. T. (2023) · Journal of the American Statistical Association · doi:10.1080/01621459.2023.2220935 · Cited by 54
Guo, W., Duan, K., Zhang, Y., Yuan, Z., Zhang, Y., Wang, Z., Zhao, D., Zhang, H., Xie, Z., Li, X., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101010 · Cited by 38
Healy, K., Pin, E., Chen, P., Söderdahl, G., Nowak, P., Mielke, S., Hansson, L., Bergman, P., Smith, C. I. E., Ljungman, P. T., et al. (2022) · Med · doi:10.1016/j.medj.2022.01.001 · Cited by 33
Myocarditis following mRNA vaccination against SARS-CoV-2, a case series
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Pardo, L. C., & Petersen, J. W. (2021) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2021.100042 · Cited by 43
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 48
A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro
Sun, J., Sun, D., Yang, Q., Wang, D., Peng, J., Guo, H., Ding, X., Zhao, C., Yuan, B., Ivanenkov, Y. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59870-4 · Cited by 44
Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 41
Xu, Y., Cui, H., Pang, K., Li, G., Gong, F., Dong, S., Wang, B., & Li, B. (2026) · Cell · doi:10.1016/j.cell.2026.01.012 · Cited by 83
Lipid Nanoparticle Delivery of Chemically Modified NGF R100W mRNA Alleviates Peripheral Neuropathy
Yu, X., Yang, Z., Zhang, Y., Xia, J., Zhang, J., Han, Q., Yu, H., Wu, C., Xu, Y., Xu, W., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202127 · Cited by 38
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine
Kirwin, E. M., Rafferty, E., Harback, K., Round, J. A., & McCabe, C. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01037-2 · Cited by 37
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Elkrief, A., Wu, J. T.-Y., Jani, C., Enriquez, K. T., Glover, M. J., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A. C., French, B. C., Jhawar, S. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1368 · Cited by 39
Mason, T. F. D., Whitston, M., Hodgson, J., Watkinson, R. E., Lau, Y.-S., Abdulrazeg, O., & Sutton, M. (2021) · BMC Medicine · doi:10.1186/s12916-021-02149-4 · Cited by 38
Santosa, A., Xu, C., Arkachaisri, T., Kong, K. O., Lateef, A., Lee, T. H., Leong, K. H., Low, A. H. L., Sriranganathan, M. K., Tan, T. C., et al. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14107 · Cited by 38
Viral vector and nucleic acid vaccines against COVID-19: A narrative review
Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.984536 · Cited by 41
Mathematical modelling of COVID-19 transmission with optimal control and cost-effectiveness analysis
Ndendya, J. Z., Mlay, G. M., & Rwezaura, H. (2024) · Computer Methods and Programs in Biomedicine Update · doi:10.1016/j.cmpbup.2024.100155 · Cited by 46
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
Zhang, X., Yuan, H., Yang, Z., Hu, X., Mahmmod, Y. S., Zhu, X., Zhao, C., Zhai, J., Zhang, X., Luo, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122145 · Cited by 41
Minimizing the ratio of ionizable lipid in lipid nanoparticles for in vivo base editing
Chen, Q., Wang, X., Zhang, Y., Tian, M., Duan, J., Zhang, Y., & Yin, H. (2024) · National Science Review · doi:10.1093/nsr/nwae135 · Cited by 42
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
Montoya, J. G., Adams, A. E., Bonetti, V., Deng, S., Link, N. A., Pertsch, S., Olson, K., Li, M., Dillon, E. C., & Frosch, D. L. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01162-21 · Cited by 42
Lee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 42
Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives
Chiappalupi, S., Salvadori, L., Vukašinović, A., Donato, R., Sorci, G., & Riuzzi, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119251 · Cited by 40
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.